Meeting Banner
Abstract #0909

Marker of disease progression in patients with relapsing remitting multiple sclerosis using 2D MRSI

Adriane Grger 1 , Vinzenz Fleischer 1 , Rupert Kolb 2 , Uwe Klose 2 , and Frauke Zipp 1

1 Department of Neurology and Neuroimaging Center (NIC), Mainz, Germany, 2 Department of Diagnostic and Interventional Neuroradiology, Magnetic Resonance Research Group, Tbingen, Germany

Our findings of increased creatine and myo-inositol levels but not different NAA levels suggest that inflammation processes are more strongly associated with early disease than neuronal loss that is correlated with disease duration. Furthermore, the higher glutamate and glutathione levels in RRMS patients receiving escalation therapy (no alter metabolites pre to post treatment with natalizumab) can be interpreted as a marker for more fulminant disease progression but not for disease duration.

This abstract and the presentation materials are available to members only; a login is required.

Join Here